Survival in low-grade and high-grade sinonasal adenocarcinoma: A national cancer database analysis.
Adenocarcinoma
National Cancer Database
grade
malignancy
overall survival
sinonasal
Journal
The Laryngoscope
ISSN: 1531-4995
Titre abrégé: Laryngoscope
Pays: United States
ID NLM: 8607378
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
received:
05
03
2019
revised:
03
04
2019
accepted:
18
04
2019
pubmed:
14
5
2019
medline:
1
7
2020
entrez:
14
5
2019
Statut:
ppublish
Résumé
The purpose of this study was to investigate survival differences between low-grade and high-grade sinonasal adenocarcinoma (SNAC) by examining demographics, tumor characteristics, and treatment modalities. Retrospective database analysis. The National Cancer Database was queried for patients with SNAC between 2004 and 2015. Univariate and multivariate analyses were performed for all cases of SNAC. Subsequent analysis focused on low-grade (grade 1 and grade 2) and high-grade (grade 3 and grade 4) SNAC. A total of 1,288 patients with SNAC were included in the main cohort and divided into low grade (n = 601) and high grade (n = 370). The 5-year overall survival for all patients, low-grade, and high-grade was 54%, 64%, and 38%, respectively. Prognostic factors associated with decreased survival for the main cohort include advanced age (hazard ratio [HR]: 1.04; 95% confidence interval [CI]: 1.03-1.06), Charlson-Deyo score (HR: 1.37; 95% CI: 1.05-1.78), grade 2 (HR: 2.21; 95% CI: 1.26-3.86], grade 3 (HR: 3.67; 95% CI: 2.09-6.45), and grade 4 (HR: 3.31; 95% CI: 1.38-7.91). Radiotherapy was associated with improved overall survival for high-grade SNAC (HR: 0.41; 95% CI: 0.24-0.70) but not for low-grade SNAC (HR: 1.05; 95% CI: 0.59-1.85). This investigation is the largest to date analyzing the association of treatment modalities with overall survival in SNAC. Surgery remains paramount to treatment, with radiotherapy offering additional survival benefit for high-grade SNAC. Administration of chemotherapy was not associated with improved survival. 4 Laryngoscope, 130:E1-E10, 2020.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
E1-E10Informations de copyright
© 2019 The American Laryngological, Rhinological and Otological Society, Inc.
Références
Chen MM, Roman SA, Sosa JA, Judson BL. Predictors of survival in sinonasal adenocarcinoma. J Neurol Surg B Skull Base 2015;76:208-213.
Kılıç S, Samarrai R, Kılıç SS, Mikhael M, Baredes S, Eloy JA. Incidence and survival of sinonasal adenocarcinoma by site and histologic subtype. Acta Otolaryngol 2018;138:415-421.
Robin TP, Jones BL, Gordon OM, et al. A comprehensive comparative analysis of treatment modalities for sinonasal malignancies. Cancer 2017;123:3040-3049.
Turner JH, Reh DD. Incidence and survival in patients with sinonasal cancer: a historical analysis of population-based data. Head Neck 2012;34:877-885.
Llorente JL, López F, Suárez C, Hermsen MA. Sinonasal carcinoma: clinical, pathological, genetic and therapeutic advances. Nat Rev Clin Oncol 2014;11:460-472.
Leivo I. Sinonasal adenocarcinoma: update on classification, immunophenotype and molecular features. Head Neck Pathol 2016;10:68-74.
Turri-Zanoni M, Battaglia P, Lambertoni A, et al. Treatment strategies for primary early-stage sinonasal adenocarcinoma: a retrospective bi-institutional case-control study. J Surg Oncol 2015;112:561-567.
Rampinelli V, Ferrari M, Nicolai P. Intestinal-type adenocarcinoma of the sinonasal tract: an update. Curr Opin Otolaryngol Head Neck Surg 2018;26:115-121.
Janz TA, Graboyes EM, Nguyen SA, et al. A comparison of the NCDB and SEER database for research involving head and neck cancer. Otolaryngol Head Neck Surg 2019;160:284-294.
Boffa DJ, Rosen JE, Mallin K, et al. Using the National Cancer Database for outcomes research: a review. JAMA Oncol 2017;3:1722-1728.
Lund VJ, Chisholm EJ, Takes RP, et al. Evidence for treatment strategies in sinonasal adenocarcinoma. Head Neck 2012;34:1168-1178.
Bhayani MK, Yilmaz T, Sweeney A, et al. Sinonasal adenocarcinoma: a 16-year experience at a single institution. Head Neck 2014;36:1490-1496.
Orvidas LJ, Lewis JE, Weaver AL, Bagniewski SM, Olsen KD. Adenocarcinoma of the nose and paranasal sinuses: a retrospective study of diagnosis, histologic characteristics, and outcomes in 24 patients. Head Neck 2005;27:370-375.
D'Aguillo CM, Kanumuri VV, Khan MN, et al. Demographics and survival trends of sinonasal adenocarcinoma from 1973 to 2009. Int Forum Allergy Rhinol 2014;4:771-776.
Haerle SK, Gullane PJ, Witterick IJ, Zweifel C, Gentili F. Sinonasal carcinomas: epidemiology, pathology, and management. Neurosurg Clin N Am 2013;24:39-49.
Bimbi G, Saraceno MS, Riccio S, Gatta G, Licitra L, Cantù G. Adenocarcinoma of ethmoid sinus: an occupational disease. Acta Otorhinolaryngol Ital 2004;24:199-203.
Chopra S, Kamdar DP, Cohen DS, et al. Outcomes of nonsurgical management of locally advanced carcinomas of the sinonasal cavity. Laryngoscope 2017;127:855-861.
Choussy O, Ferron C, Védrine PO, et al. Adenocarcinoma of ethmoid: a GETTEC retrospective multicenter study of 418 cases. Laryngoscope 2008;118:437-443.
Robbins KT, Ferlito A, Silver CE, et al. Contemporary management of sinonasal cancer. Head Neck 2011;33:1352-1365.
Suh JD, Ramakrishnan VR, Chi JJ, Palmer JN, Chiu AG. Outcomes and complications of endoscopic approaches for malignancies of the paranasal sinuses and anterior skull base. Ann Otol Rhinol Laryngol 2013;122:54-59.
Hanna E, DeMonte F, Ibrahim S, Roberts D, Levine N, Kupferman M. Endoscopic resection of sinonasal cancers with and without craniotomy: oncologic results. Arch Otolaryngol Head Neck Surg 2009;135:1219-1224.
Lund VJ, Stammberger H, Nicolai P, et al. European position paper on endoscopic management of tumours of the nose, paranasal sinuses and skull base. Rhinol Suppl 2010;22:1-143.